Page results
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This page is for patients who have been referred on a suspected cancer pathway.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
File results
-
FOI/2023/0005 - Endoscopy numbers - inflammatory bowel disease
-
FOI/2023/0007 - Outpatient activity for 2022
-
FOI/2023/0009 - Procedure volumes/ average costs for portable and stable oxygen concentrator devices
-
FOI/2023/0010 - Bardet-biedle Syndrome patient treatment and diagnosis
-
FOI/2023/0013 - Average waiting times for colonoscopy investigations
-
FOI/2023/0014 - Surgery protocols/ standard operating procedures for a feticide
-
FOI/2023/0018 - A&E attendances/ admissions by patients of no fixed abode
-
FOI/2023/0019 - Public access to water refill stations on your premises
-
FOI/2023/0022 - Guidelines staff follow for patients with disabilities and autism
-
FOI/2023/0226 - Treatment with Nivolumab